Cargando…

Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers

The assessment of EGFR mutations is recommended for the management of patients with non-small cell lung cancer (NSCLC). Presence of EGFR mutation is associated with response or resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI). Liquid biopsy is nowadays widely used for the detection of resist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilson, Pauline, Saurel, Chloé, Salleron, Julia, Husson, Marie, Demange, Jessica, Merlin, Jean-Louis, Harlé, Alexandre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131701/ https://www.ncbi.nlm.nih.gov/pubmed/34006948 http://dx.doi.org/10.1038/s41598-021-90091-z

Ejemplares similares

Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers
por: Gilson, Pauline, et al.
Publicado: (2023)

Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers
por: Gilson, Pauline, et al.
Publicado: (2020)

Accelerated BRAF mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma
por: Serre, Delphine, et al.
Publicado: (2018)

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines
por: Witz, Andréa, et al.
Publicado: (2023)

Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing
por: Franczak, Claire, et al.
Publicado: (2019)

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples
por: Offerman, Saskia, et al.
Publicado: (2021)

Contribution of the Idylla(TM) System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations
por: Petiteau, Constance, et al.
Publicado: (2021)

Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma
por: Franczak, Claire, et al.
Publicado: (2019)

Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review
por: Caputo, Alessandro, et al.
Publicado: (2021)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer
por: Franczak, Claire, et al.
Publicado: (2020)

Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation
por: Gilson, Pauline, et al.
Publicado: (2019)

Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available
por: Ercolani, Cristiana, et al.
Publicado: (2022)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
por: Delgado-García, Mercedes, et al.
Publicado: (2020)

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
por: Suda, Kenichi, et al.
Publicado: (2023)

Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
por: Gilson, Pauline, et al.
Publicado: (2021)

Ultra-rapid Idylla™ EGFR mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer
por: Qiu, Tian, et al.
Publicado: (2023)

Advanced Non-small Cell Lung Cancer: EGFR Mutation Analysis Using Pyrosequencing and the Fully Automated qPCR-Based Idylla(TM) System
por: Boustany, Youssra, et al.
Publicado: (2023)

Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma
por: Harlé, Alexandre, et al.
Publicado: (2016)

Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer
por: Ilie, Marius, et al.
Publicado: (2017)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform
por: Banyi, Norbert, et al.
Publicado: (2022)

Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations
por: Cho, Yong Gon, et al.
Publicado: (2023)

Evaluation and validation of HPV real-time PCR assay for the detection of HPV DNA in oral cytobrush and FFPE samples
por: Harlé, Alexandre, et al.
Publicado: (2018)

Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
por: Hoshi, Hirotaka, et al.
Publicado: (2017)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy
por: Gilson, Pauline, et al.
Publicado: (2022)

EGFR Mutations and Lung Cancer
Publicado: (2005)

ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
por: Betz, Margaux, et al.
Publicado: (2023)

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
por: Vivancos, Ana, et al.
Publicado: (2019)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
por: Phan, Thang Thanh, et al.
Publicado: (2019)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer
por: Ukkola, Iiris, et al.
Publicado: (2021)

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
por: Hackner, Klaus, et al.
Publicado: (2021)

Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
por: Murakami, Shuji, et al.
Publicado: (2022)

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay
por: Guo, Qiao-mei, et al.
Publicado: (2019)

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform
por: Bisschop, Cornelis, et al.
Publicado: (2018)

Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays
por: Jiang, Xi-Wen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_urmmmn81lp8fkn0scjd03kn33q